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Abstract
Objectives: Human epidermal growth factor receptor type
2 (HER2)-expressing breast cancer patients indicate poor
prognosis in disease progression. HER2 overexpression can
increase activities of Ras-mitogen activated protein kinase
(Ras-MAPK) pathway and Janus Kinase (JAK)-STAT3,
increasing breast cancer cell proliferation as demonstrated
by marker Ki67. Therapeutic options for HER2-expressing
breast cancer are limited and have major side effects, so
anticancer development as an antiproliferative is needed.
From previous research, synthetic chemical 4-(tert-butyl)-
N-carbamoylbenzamide (4TBCB) compound has cytotoxic
activity in vitro on HER2-expressing breast cancer cells.
This study wanted to determine the mechanism 4TBCB
compound in inhibiting HER2 signaling through Rat Sar-
coma (Ras) and signal transducer and activator of tran-
scription 3 (STAT3) pathway in HER2-expressing breast
cancer cells.
Methods: Breast cancer cells were isolated from the
biopsy tissue of breast cancer patients. The isolated cells
were cultured and given 4TBCB test compound with three
concentrations (0.305, 0.61, and 1.22 mM) and lapatinib
0.05 mM as a comparison compound. Cancer cell cultures
were stained with monoclonal antibodies phosphorylated
HER2 (pHER2), phosphorylated Ras (pRas), phosphory-
lated STAT3 (pSTAT3), and Ki67. The expression of pHER2,
pRas, pSTAT3, and Ki67 proteins was observed using the
immunofluorescence method and the results were
compared with control cells, namely cancer cells that were
not given 4TBCB and lapatinib but stained with mono-
clonal antibodies.
Results: 4TBCB compounds (0.61 and 1.22 mM) and lapa-
tinib can reduce pHER2, pRas, pSTAT3, and Ki67 expres-
sions compared to control cells.
Conclusions: 4TBCB compounds (0.61 and 1.22 mM) can
reduce pHER2, pRas, pSTAT3, Ki67 expressions and pre-
dicted to inhibit HER2 signaling through the Ras and STAT3
pathways in HER2-expressing breast cancer cells.
Keywords: antiproliferative; breast cancer cells; HER2;
Ras; STAT3; 4-(tert-butyl)-N-carbamoylbenzamide.
Introduction
Breast cancer is the second most malignant disease of all
types of cancers in the world in 2018 and becomes an
alarming disease for women around the world [1]. Twenty-
five to thirty percent of patients with breast cancer are
expressedwithhumanepidermal growth factor receptor type
2 (HER2) excessively and this correlates with the increase of
aggressiveness, poor prognosis, and shorter survival periods
[2, 3]. HER2 is a family of human epidermal growth factor
receptor (HER) that has a tyrosine kinase activity. HER2 re-
ceptor dimerization causes autophosphorylation of tyrosine
residues in the cytoplasmic intracellular domain, thus, it
activates HER2 signaling pathways, including Ras-mitogen
activated protein kinase (Ras-MAPK) pathway, signal trans-
ducer and activator of transcription 3 (STAT3) and phos-
phoinositide-3-kinase-Akt (PI3K-Akt). Activating the HER2
signaling pathway leads to cell proliferation, cell differenti-
ation, adhesion, migration, as well as cell survival [4–6].
HER2 activation enhances the level of Rat Sarcoma (Ras). In a
study conducted by Eckert, five out of nine breast cancer cell
lines exhibit an increase of the active Ras-GTP level due to
HER-2 activation [7]. The active Ras phosphorylates and
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activates the next Raf, and subsequently activates Mitogen-
Activated Protein/Extracellular Signal-Regulated Kinase
(MEK)andErk1 andErk2 [5, 7]. Ras-MAPKpathway involves a
protein kinase cascade which contributes to regulate cell
proliferation and cell survival [8, 9]. The activation of the
STAT3pathwayonHER2 overexpressionhas been studiedby
Chung in breast cancer cell culture. His research stated that
the STAT3 mRNA expression increased 3.62 times in Michi-
gan Cancer Foundation (MCF)-7/HER2 compared to MCF-7-
cell culture [10].
Ki67 is a marker related to cell proliferation assessing
the growth of malignant cells. Ki67 is expressed
throughout the cell cycle and the peaks during mitosis and
at a lesser extent in normal breast tissue from estrogen
receptor negative cells than in breast cancer tissue.
Therefore, Ki67 can be used as an additional factor for
decision making in developing treatment strategies for
breast cancer patients [11].
HER2 positive breast cancer therapy is limited, with
major side effects. One anticancer used for HER2 positive
breast cancer is lapatinib, a tyrosine kinase inhibitor that
inhibits the phosphorylation of tyrosine residues in the
intracellular domain of the HER2 and EGFR cytoplasmic re-
ceptors, which causes inhibition of intracellular signaling
pathways that reduce cell proliferation and induce apoptosis
[12]. Currently, lapatinib is known to build resistance in a
number of breast cancer patients [12, 13]. This is a significant
underlying cause for developing new anticancer drugs with
maximum therapeutic effect in inhibiting HER2 signaling in
the Ras and STAT3 pathways.
Urea-derivative compounds have been extensively
developed due to its cytotoxic activity against breast cancer
cell lines. The synthesis of N-(phenylcarbamothioyl)-benza-
mide derivatives againstMCF-7 cell lines has been reported to
have better IC50 value compared to hydroxyurea, the least
complex derivative of urea [14]. Li et al., synthesized and
investigated the structure–activity relationship of N-benzyl-
N-(X-2-hydroxybenzyl)-N′-phenylureas derivative compound
and thiourea derivatives and found them to potentially
inhibit EGFR and HER2 kinase, as well as inhibit MCF-7 cell
proliferation [2]. The docking, synthesis, and cytotoxic test
against T47D cell lines on N-(allylcarbamothioyl) benzamide
compounds, yielded better outcome on IC50 (56.50 μg/mL)
compared to 5-fluorouracil (5FU=132.37 μg/mL) [15].
Another way to develop anticancer drugs is by structure
modification. The 4-(tert-butyl)-N-carbamoylbenzamide
(4TBCB) compound is derived from structure modification of
a parent compound N-carbamoylbenzamide aiming to
enhance its cytotoxic activity. From previous research, it has
known that 4TBCB cytotoxic activity of HER2-expressing
breast cancer cells using theMTT (Microculture Tetrazolium)
method gave an IC50 value of 0.61mMand hydroxyureawith
an IC50 value of 11.61 mM. This suggests that 4TBCB com-
pounds have better cytotoxic activity to choose compared to
hydroxyurea [16]. Therefore, 4TBCB can be used as anti-
cancer candidates for HER2-expressing breast cancer.
Meanwhile, this study aims to investigate the mechanism of
the 4TBCB as an inhibitor of HER2 signaling on Ras and
STAT3 pathway against HER2-expressing breast cancer cells.
Materials and methods
Isolation of breast cancer cells
This research is under the approval of theHealth andResearch, Ethical
Commission of RSUD Dr. Soetomo Surabaya with ethical clearance
number 1456/KEPK/VIII/2019. Breast cancer cells were isolated from
the biopsy tissue of breast cancer patient, washed with NaCl solution,
chopped and given 0.075% collagenase type 1 (Worthington, USA) for
45 min at 37 °C, then filtered with cell strainer. The supernatant
obtained was centrifuged at 3,000 rpm for 5 min. Cell pellets were
washed with PBS and centrifuged again for 5 min. Cell pellets were
cultured in alpha Minimal Essential Medium (MEM) (Gibco, USA) with
the addition of 10% FBS (Gibco, USA), 1% L-glutamine (Gibco, USA),
1% penicillin–streptomycin (Gibco, USA), and 1% amphotericin B
(Sigma-Aldric, USA), then incubated in a CO2 incubator at 37 °C. The
medium was replaced every 3 days and after the cells reached 90%,
confluent cell passage was carried out [17]. After isolation, cells were
identified against cell surfacemarkers (CD24, CD44, andCD90) byflow
cytometry to ensure that the isolated cellswere breast cancer cells. The
cells were identified using HER2 immunofluorescence monoclonal
antibody.
Expressions of pHER2, pRas, pSTAT3, and Ki67 protein
using immunofluorescence assay
The 4TBCB was used as test compound and lapatinib as compared.
The 4TBCBwasmade in three concentrations of 0.305mM (0.5 × IC50),
0.61 mM (1 × IC50), and 1.22 mM (2 × IC50), while lapatinib 0.05 mM
(1× IC50) was based on in vitro cytotoxicity tests using theMTTmethod.
From the cytotoxicity test, the IC50 values of 4TBCB and lapatinibwere
0.61mM (1 × IC50) and 0.05mM (1 × IC50), respectively [16]. The protein
expressions observed were pHER2, pRas , pSTAT3 and Ki67. Each
protein expression was observed in five groups of cancer cells con-
sisting of three groups of cancer cells given 4TBCB compounds with
concentrations of 0.305, 0.61, and 1.22 mM. Meanwhile, one group of
cancer cells was given 0.05 mM lapatinib, and one control group of
cancer cells was not given 4TBCB and lapatinib, but only given
monoclonal antibodies (pHER2, pRas, pSTAT3, and Ki67). Each group
of cells was made on five replications.
Breast cancer cells were planted on 24 well plates totaling
105 cells/1,000µL/well, then incubated in aCO2 incubator at 37 °Cuntil
reaching 90% confluent. Cell cultures that have reached 90%
confluent were given 4TBCB and lapatinib according to the prepared
concentrations, then incubated again for 24 h, followed by cell culture
fixation using methanol for 15 min, then washed twice with PBS
(Sigma Aldrich, USA) – tween 0.2%. The cells were then given
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TritonX100 (Sigma Aldrich, USA) 0.5% for 5 min to cell per-
meabilization and washed with 0.2% PBS tween three times for 1 min.
Furthermore, the cells were given a blocking solution of 1% BSA
(Sigma Aldrich, USA) for 30 min, then washed with 0.2% PBS tween
and stainedwithmonoclonal antibodies (Biolegend). Themonoclonal
antibodies were diluted in a ratio of 1:100 in BSA. Cells that have been
stained with monoclonal antibodies were then incubated overnight in
a container wrapped in aluminum foil. Furthermore, the cells were
given secondary antibody labeled FITC and incubated for 1 h. The
results were observed using a 100× fluorescence microscope (Auto-
mated Fluorescence Microscope, BX63, Olympus, USA) magnification
[17]. If the cells express the pHER2, pRas, pSTAT3, and Ki67 proteins,
the cells will fluoresce green. Fluorescence microscopy was observed
over 10 large viewing areas for each cell replication. In the immuno-
fluorescence method, negative control cells were needed to validate
the method. Negative control cells were cancer cells that were not
given 4TBCB, lapatinib, and monoclonal antibodies. Negative control
cells must not provide fluorescence to certify that the immunofluo-
rescence method is valid, these cells were not included in the study
cell group, but only to validate the method.
Statistical analysis
Immunofluorescence visualization images were transferred into the
ImageJ program to obtain quantitative data in numerical form, but
there is no unit for data [18, 19]. The numerical data obtained were
analyzed statistically using one way ANOVA or Kruskal Wallis
depending on the normality and homogeneity of the data, and then
continuedwith the post hoc test with the Tukey or Mann-Whitney test.
The statistical analysis was performed using the SPSS version 25 pro-
gram and the data was said to be statistically significant if the p value
was ≤0.05.
To examine the relationship between pHER2, pRas, pSTAT3, and
Ki67 variables in predicting the mechanism of action of 4TBCB, path
analysis was used. From the path analysis, the β coefficients and
p value will be obtained. The coefficient β shows the magnitude of the
direct effect on a variable and p value shows the significance of the
effect on that variable.
Results
Identification of breast cancer cells by flow cytometry and
immunofluorescence is shown in Figures 1 and 2.
Figure 1 shows the number of cancer cells in the right
upper quadrant, which express a combination of cell sur-
face markers. Cells that express CD24, CD44, and CD90 are
indicated as breast cancer cells. CD24, CD44, and CD90 are
cell surface markers commonly found in solid tumor, one
of which is breast cancer [20, 21].
Figure 2 shows that breast cancer cells fluoresce green,
meaning that they express the HER2 protein. The immu-
nofluorescence visualization of breast cancer cells
expressing pHER2, pRas, pSTAT3, and Ki67 proteins and
mean graph of target protein expression are shown in
Figures 3–6.
Statistical analysis of pHER2 expression tested using
Kruskal Wallis showed significant difference in the 95%
confidence level between groups of breast cancer cells, and
Mann Whitney test showed no significant difference
(p>0.05) between the control group and the 4TBCB
0.305 mM group. This shows that 4TBCB 0.305 mM com-
pound does not inhibit HER2 phosphorylation, so that it
does not decrease pHER2 expression in breast cancer cells.
The 4TBCB 0.61 mM group, 4TBCB 1.22 mM group, and the
lapatinib group were significantly different from the con-
trol cell group. This suggests that 4TBCB 0.61, 1.22mM, and
lapatinib can inhibit HER2 phosphorylation thus reducing
pHER2 expression. The decrease in pHER2 expression was
in line with the increase in the concentration of 4TBCB
(Figure 3F).
The pRas expression analyzed using one way ANOVA
showed a significant difference in the 95% confidence level
between cell groups, followed by the Tukey test showing
significant difference (p≤0.05) between all the 4TBCB
compound groups and the control cell group, as well as the
lapatinib group was significantly different from the control
cell group. This suggests that 4TBCB compounds ranging
at 0.305–1.22 mM can inhibit intracellular signals that
inhibit Ras phosphorylation thus reducing pRas expres-
sion. Lapatinib can also decrease pRas expression in breast
cancer cells. The decrease in pRas expression alongwith an
increase in the concentration of 4TBCB is shown in
Figure 4F.
Figure 1: Identification of breast cancer cells
by flow cytometry. Breast cancer cells
expressing CD44/CD90 (A). Breast cancer
cells expressing CD90/CD24 (B).
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Statistical calculation of pSTAT3 expression tested
using one way ANOVA showed a significant difference in
the 95% confidence level between groups of breast
cancer cells, followed by Tukey test showing no signifi-
cant difference between the 4TBCB 0.305 mM group
and the control cell group. This indicates that 4TBCB
Figure 2: Identification of breast cancer
cells expressing human epidermal growth
factor receptor type 2 (HER2) by
immunofluorescence. Phase-contrast
(A) and immunofluorescence visualization
(B) of HER2-expressing cells.
Figure 3: Visualization of immunofluorescence of breast cancer cells expressing phosphorylated human epidermal growth factor receptor
type 2 (pHER2) and mean graph pHER2 expression. The red arrow shows breast cancer cells that express pHER2. Immunofluorescence
visualization of control cells (A); 4-(tert-butyl)-N-carbamoylbenzamide (4TBCB) 0.305mMgroup (B); 4TBCB0.61mMgroup (C); 4TBCB 1.22mM
group (D); lapatinib group (E); and mean graph of pHER2 protein expression in breast cancer cells (F).
Figure 4: Visualization of immunofluorescence of breast cancer cells expressing phosphorylated Ras (pRas) and mean graph pRas
expression. The red arrows indicate breast cancer cells that express pRas. Immunofluorescence visualization of control cells (A); 4-(tert-butyl)-
N-carbamoylbenzamide (4TBCB) 0.305 mM group (B); 4TBCB 0.61 mM group (C); 4TBCB 1.22 mM group (D); lapatinib group (E); and mean
graph of pRas protein expression in breast cancer cells (F).
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0.305 mM compound does not inhibit intracellular
signaling so that it does not inhibit STAT3 phosphory-
lation; as a result pSTAT3 expression does not decrease
in breast cancer cells. The 4TBCB 0.61 mM, 4TBCB
1.22 mM, and lapatinib groups were significantly
different from the control cell groups, so, it can be said
that the compound 4TBCB 0.61 mM, 4TBCB 1.22 mM, and
lapatinib can reduce the pSTAT3 expression in breast
cancer cells (Figure 5F).
Statistical analysis using Kruskal Wallis on Ki67
expression showed a significant difference in the 95%
confidence level between groups of breast cancer cells,
followed by the Mann Whitney test showing no significant
difference between the 4TBCB 0.305 mM and lapatinib and
the control cell group. This means that 4TBCB 0.305 mM
compound cannot reduce the Ki67 expression as well as
lapatinib. The 4TBCB 0.61 mM and 4TBCB 1.22 mM groups
were significantly different from the control cell group,
meaning that the two groups of 4TBCB compounds could
reduce Ki67 expression and decrease Ki67 expression
along with the increase in the concentration of 4TBCB
compounds (Figure 6F).
The relationship between variables was analyzed
using path analysis to determine the mechanism of action
of the 4TBCB compound. The path analysis chart is shown
in Figure 7. Prediction of HER2 signaling inhibition on the
Ras and STAT3 pathway due to 4TBCB administration is
shown in Figure 8.
Figure 5: Visualization of immunofluorescence of breast cancer cells expressing phosphorylated signal transducer and activator of
transcription 3 (pSTAT3) and mean graph pSTAT3 expression. The red arrows indicate breast cancer cells that express pSTAT3.
Immunofluorescence visualization of control cells (A); 4-(tert-butyl)-N-carbamoylbenzamide (4TBCB) 0.305 mM group (B); 4TBCB 0.61 mM
group (C); 4TBCB 1.22 mM group (D); lapatinib group (E); and mean graph of pSTAT3 protein expression in breast cancer cells (F).
Figure 6: Visualization of immunofluorescence of breast cancer cells expressing Ki67 and mean graph Ki67 expression. The red arrows
indicate breast cancer cells that express Ki67. Immunofluorescence visualization of control cells (A); 4-(tert-butyl)-N-carbamoylbenzamide
(4TBCB) 0.305 mM group (B); 4TBCB 0.61 mM group (C); 4TBCB 1.22 mM group (D); lapatinib group (E); and mean graph of Ki67 protein
expression in breast cancer cells (F).
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Based on Figure 7, the 4TBCB compound has a nega-
tive β coefficient value (−0.973) and is significant to the
pHER2 expression (p = 0.000). This means that 4TBCB has
a direct effect on the pHER2 expression by reducing the
pHER2 by −0.973. The decrease in pHER2 expression also
has a direct effect on the decrease in praise and pSTAT3
expressions by 0.963 and 0.956, respectively. The decrease
in pRas and pSTAT3 expressions directly affects the
decrease in Ki67 expression.
Figure 8 is a prediction of the mechanism of action of
4TBCB in inhibiting HER2 signaling through the Ras and
STAT3 pathways in breast cancer cells. By inhibiting HER2
protein phosphorylation, it is predicted that there will be
inhibition of intracellular signal through the Ras and
STAT3 pathways so that a decrease in cancer cell prolifer-
ation is indicated by a decrease in Ki67 expression.
Discussion
Figure 3F proves that 4TBCB 0.61 and 1.22 mM compounds
work by inhibiting HER2 phosphorylation in the intracel-
lular domain so that there is a decrease in pHER2 expres-
sion. The parameter of physical–chemical properties that
plays the most important role in the distribution process of
drugs in the body is the lipophilic parameter. Lipophilic
parameters often used are the logarithm of the partition
coefficient (log P) and theHansh–Fujita π constant. The log
P prediction of 4TBCB using the ChemDraw program was
2.26, while the N-carbamoylbenzamide parent compound
had a predictive log P 0.56. Based on the value of the
substituted constant used in aromatic substitution ac-
cording to the Topliss approach model, the 4-t-butyl group
has lipophilic properties with a value of π = 1.98 [22]. The
presence of this group increased the lipophilic properties of
the 4TBCB. Therefore, log P and π constant predicted that
4TBCB has good lipophilic properties to penetrate cell
membranes well. The decreased expression of pHER2
protein causes an intracellular signal to phosphorylate Ras
and STAT3 to be inhibited, thereby inhibiting DNA repli-
cation, which results in decrease in proliferation of
HER2-expressing breast cancer cells.
Figure 7: The path analysis of 4-(tert-butyl)-N-carbamoylbenzamide
(4TBCB) compound.
Figure 8: Prediction of HER2 signaling
inhibition on the Ras and signal transducer
and activator of transcription 3 (STAT3)
pathway due to 4-(tert-butyl)-N-
carbamoylbenzamide (4TBCB)
administration.
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The 4TBCB ranging from0.305 to 1.22mM can decrease
the pRas protein expression. The decrease in pRas protein
expression is in line with the increase in the concentration
of 4TBCB compound (Figure 4F). Ras genes encode Ras
protein that play a role in intracellular signal transduction
to trigger cellmultiplication. This protein displays different
conformational forms, Ras-GDP (Ras-Guanine Diphos-
phate) when inactive, and Ras-GTP (Ras-Guanine
Triphosphate) while active. The balance between Ras-GDP
and Ras-GTP is regulated by guanine nucleotide exchange
factor (GEF) and GTPase activating protein (GAP). Ras-GDP
(in the “off” state) is transformed into Ras-GTP (in the “on”
state) by the GEF enzyme. On the contrary, the “on” to “off”
position is regulated by the enzyme GAP [23–25]. In breast
cancer, Ras is activated by overexpressing HER2 and acti-
vating signal transduction to the nucleus by simulta-
neously activating the target effectors (RAF, MEK, and
Extracellular Signal-Regulated Kinase [Erk]). The contin-
uous activation of Ras-MAPK triggers an increase in the
number of DNA replications and cell proliferation [5, 7].
Therefore, 4TBCB was proven to inhibit HER2 phosphory-
lation, which inhibits the activation of Ras pathway and
causes the pRas expression to decrease.
The pSTAT3 expression analysis proved that 4TBCB at
0.61 and 1.22 mM inhibited HER2 intracellular signals
which resulted in inhibition of STAT3 phosphorylation and
decreased pSTAT3 expression (Figure 5F). STAT3 is a
transcription factor that regulates transcription and gene
expression in cellular processes. STAT3 can be activated
in all breast cancer subtypes. Various tyrosine kinase
receptors (EGFR, HER2, and VEGF) can phosphorylate
STAT3 in breast cancer [11, 26].
The Ki67 expression analysis showed a decrease in
Ki67 expression in line with the increase in concentration
of the 4TBCB compound (0.61 and 1.22 mM) (Figure 6F).
Ki67 is a core protein associated with cell proliferation,
expressed in the cell cycle in the S, G1, G2, and M phases in
the nucleus. Ki67 expression differs from phase-to-phase
and peaks during mitosis. Therefore, Ki67 is used as a
marker to evaluate cell proliferation to determine specific
therapy for each patient [11, 27]. The classification in
molecular subtypes of breast cancer states that the luminal
B and HER2 overexpression had the highest Ki67 index in
accordance with a study conducted by Hashmi and Ragab
on patients with breast cancer in hospitals [11, 27]. This
research suggested that 4TBCB lowered Ki67 expression
led to lower proliferation of HER2-expressing breast
cancer cells.
Lapatinib is clinically used as anticancer for
HER2-positive breast cancer patients. Lapatinib is a
tyrosine kinase inhibitor that selectively inhibits
HER2 and EGFR [28]. The analysis results shown in Fig-
ures 3F–5F prove that lapatinib can reduce the expres-
sion of pHER2, pRas, and pSTAT3. This study has shown
that lapatinib did not decrease Ki67 expression, possibly
because there are other intracellular signaling pathways
other than the Ras and STAT3 pathways that can activate
cell proliferation so that Ki67 expression remains high
with lapatinib administration. In this study, 4TBCB was
compared with lapatinib which is clinically used as
anticancer, so it can be said that 4TBCB has a potential to
be an anticancer. However, 4TBCB required a greater
concentration in reducing pHER2, pRas, pSTAT3, and
Ki67, namely 0.61 mM (1 × IC50) compared to lapatinib at
0.05 mM (1 × IC50).
The mechanism of action of the 4TBCB can be
explained using path analysis between variables. Based on
the results of path analysis, 4TBCB is predicted to work
through inhibition of HER2 signaling on the Ras and STAT3
pathways in HER2-expressing breast cancer cells.
The 4TBCB compound as awhole is predicted to inhibit
HER2 signaling in the Ras and STAT3 pathways shown in
the graph in Figure 8. Inhibition of HER2 phosphorylation
inhibits Ras protein activation thus Raf effectors are not
recruited and subsequently do not activate Mek1/2 and
Erk1/2. Erk1/2 is a transcription factor that plays a role in
the synthesis of proteins required for DNA replication in
cancer cells. Inhibited Erk1/2 activation will decrease DNA
replication, thus decreasing cell proliferation. The inhibi-
tion of HER2 phosphorylation also inhibits Janus Kinase
(JAK) activation, thereby inhibiting STAT3 phosphoryla-
tion. STAT3 phosphorylation increases cyclin D1 mRNA
expression, causing the formation of complex cyclin D1
bonds with CDK4 and CDK6 [29, 30]. These complex bonds
cause pRB phosphorylation and then activate transcription
factor E2F1, which mediate the synthesis of cdc 6p protein
needed to trigger the formation of O replication bubbles
that DNA replication occurs [25]. The inhibition of STAT3
activation due to HER2 phosphorylation inhibition causes
DNA replication to decrease and cancer cell proliferation
will also decrease. Therefore, 4TBCB compound can be
said to be a candidate for antiproliferative agent for
HER2-expressing breast cancer cells.
Conclusions
4TBCB compounds at concentrations of 0.61 and 1.22 mM
have been shown to reduce the expression of pHER2, pRas,
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pSTAT3, and Ki67 proteins and are thought to have an
inhibitory mechanism of HER2 signaling through the
Ras and STAT3 pathways on HER2-expressing breast
cancer cells.
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